Entrada Therapeutics
TRDA
114 hedge funds and large institutions have $269M invested in Entrada Therapeutics in 2025 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 42 reducing their positions, and 15 closing their positions.
103% more call options, than puts
Call options by funds: $229K | Put options by funds: $113K
50% more capital invested
Capital invested by funds: $179M → $269M (+$90.1M)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
3% less funds holding
Funds holding: 117 → 114 (-3)
10.97% less ownership
Funds ownership: 79.44% → 68.47% (-11%)
17% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 42
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$12.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$1.74M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.2M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$935K |
| 5 |
BlackRock
New York
|
+$870K |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$2.88M |
| 2 |
Millennium Management
New York
|
-$2.86M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
-$1.69M |
| 4 |
Jane Street
New York
|
-$1.36M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.02M |
TRDA Hedge Fund Activity: Q4 2025 in Review
114 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2025, worth a combined $269M — up 50% from $179M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TRDA positions and 15 closed out — a net gain of 1 holder — while 35 added to existing stakes and 42 trimmed.
The largest buyer was TCG Crossover Management, adding an estimated $12.7M. The largest seller was Renaissance Technologies, cutting an estimated $2.88M.
- 114 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2025, down from 117 in Q3 2025.
- Funds reported $269M of Entrada Therapeutics stock for Q4 2025, up 50% quarter-over-quarter.
- 16 funds opened new Entrada Therapeutics positions in Q4 2025 and 15 closed out, a net change of +1 holder.
- The largest Entrada Therapeutics buyer in Q4 2025 was TCG Crossover Management, an estimated $12.7M added.
- The largest Entrada Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $2.88M sold.
Based on aggregated 13F filings for Q4 2025.